HomeCompareLIAN vs PEP

LIAN vs PEP: Dividend Comparison 2026

LIAN yields 134.80% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LIAN wins by $14.57M in total portfolio value
10 years
LIAN
LIAN
● Live price
134.80%
Share price
$0.32
Annual div
$0.43
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.72M
Annual income
$5,984,170.20
Full LIAN calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — LIAN vs PEP

📍 LIAN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLIANPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LIAN + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LIAN pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LIAN
Annual income on $10K today (after 15% tax)
$11,457.68/yr
After 10yr DRIP, annual income (after tax)
$5,086,544.67/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, LIAN beats the other by $5,032,628.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LIAN + PEP for your $10,000?

LIAN: 50%PEP: 50%
100% PEP50/50100% LIAN
Portfolio after 10yr
$7.43M
Annual income
$3,023,800.35/yr
Blended yield
40.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

LIAN
Analyst Ratings
1
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-2.4
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LIAN buys
0
PEP buys
0
No recent congressional trades found for LIAN or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLIANPEP
Forward yield134.80%3.66%
Annual dividend / share$0.43$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$14.72M$144.7K
Annual income after 10y$5,984,170.20$63,430.49
Total dividends collected$13.51M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: LIAN vs PEP ($10,000, DRIP)

YearLIAN PortfolioLIAN Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$24,180$13,479.62$10,854$514.44+$13.3KLIAN
2$56,333$30,460.96$11,982$758.21+$44.4KLIAN
3$126,601$66,324.55$13,526$1,136.44+$113.1KLIAN
4$274,767$139,304.02$15,727$1,741.93+$259.0KLIAN
5$576,559$282,557.87$19,012$2,750.28+$557.5KLIAN
6$1,171,036$554,118.18$24,173$4,514.44+$1.15MLIAN
7$2,304,838$1,051,829.48$32,789$7,793.80+$2.27MLIAN
8$4,400,957$1,934,780.61$48,258$14,354.51+$4.35MLIAN
9$8,161,691$3,452,667.04$78,586$28,686.63+$8.08MLIAN
10$14,717,180$5,984,170.20$144,688$63,430.49+$14.57MLIAN

LIAN vs PEP: Complete Analysis 2026

LIANStock

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Full LIAN Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this LIAN vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LIAN vs SCHDLIAN vs JEPILIAN vs OLIAN vs KOLIAN vs MAINLIAN vs MOLIAN vs PMLIAN vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.